Pathways in Managing Ulcerative Colitis

Slides:



Advertisements
Similar presentations
Con: Asymptomatic Ulcerative Colitis Patients on an Immunomodulator with Persistent Moderate Mucosal Inflammation Should Not Add A Biologic or Switch to.
Advertisements

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Cure’s GTX Licensing Opportunity
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
INTRODUCTION  Comparative effectiveness research (CER) is an emerging field that compares the relative effectiveness of alternative strategies to prevent,
Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
Dr. Gholam Reza Khatami Ulcerative colitis is a chronic gastrointestinal disease Given modern treatment, medical management is not curative.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
You Can Never Stop a Biologic
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Baumgart, D C The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis Dtsch Arztebl Int 2009; 106(8): ; DOI: /arztebl
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis SANDRO ARDIZZONE,* ANDREA CASSINOTTI,*
Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.
R3. 최태웅 / Pf. 김효종 Alimentary Pharmacology & Therapeutics 19 FEB 2016 DOI: /apt.13547
BACKGROUND  Acute severe ulcerative colitis (ASUC)  Medical emergency  I.V corticosteroid : mainstay management the past 40 years  One-third of patients.
Cumulative Probability of Developing Colon Cancer in UC Patients
The Nurse’s Role in Inflammatory Bowel Disease
P0866 Combination of Low dose Thiopurine and Allopurinol in patients with ulcerative colitis Please export the Keynote document as a PDF (File – Save as.
IBD Therapies: Guidance for Managed Care Professionals
Clinical Trials in IBD.
Strategies for Mucosal Healing in Crohn Disease
Issue Highlights Clinical Gastroenterology and Hepatology
Goals of Therapy for Patients With UC
Optimizing Use of Biological Agents in Ulcerative Colitis
Changing the IBD Paradigm
Complicated Cases in Ulcerative Colitis
Comparing Treatment Alternatives in Ankylosing Spondylitis
A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.
Optimizing Patient Outcomes in IBD
The Vicious Cycle of Chronic Migraine How Can the Physician Help?
Volume 143, Issue 2, Pages e1 (August 2012)
The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to- Moderately Active Ulcerative Colitis  Ajit Sood, Vandana Midha, Govind K.
Clinical Updates in RA: New Developments and Insights From Washington
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
Managing IBD.
Illustrations in Ulcerative Colitis
Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens,
Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.
A 31-Year-Old Patient With Colitis and Perianal Disease
Advancing the Treatment of IBD With Biologics
When Is Biologic Therapy Appropriate for HS?
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Article by: Zubin Grover , Richard Muir, and Peter lewindon
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
Early Referral for Patients With IBD Failing Conventional Therapies
What's New in Therapeutic Options for Moderate to Severe RA?
Optimizing Outcomes in Crohn Disease
Volume 146, Issue 1, Pages e1 (January 2014)
Application of Biologics in IBD:
Volume 149, Issue 7, Pages e2 (December 2015)
Incorporating Prostacyclins Into Practice
Clinical Gastroenterology and Hepatology
Volume 150, Issue 5, Pages (May 2016)
Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis  Shailja C.
Pathogenesis of IBD, and the Role of Biologic Therapies
Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis  David N. Moskovitz, Gert Van Assche,
Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease  Guillaume Bouguen, Barrett G.
Presentation data from US VICTORY Consortium
Crohn’s Disease Biologic Pathway
Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.
Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.
IBD: A Comorbidity of PSC
Patient Heterogeneity in CD
Endoscopic picture of ulcerative colitis with (A) Mayo grade 3 score with friable mucosa and large ulcers. Endoscopic picture of ulcerative colitis with.
Women With Psoriasis Are Struggling More Than Men
Presentation transcript:

Pathways in Managing Ulcerative Colitis

AGA Diagnosis and Treatment of UC

Case Initial Assessment of a Young Woman

Case Laboratory and Colonoscopy Findings

Endoscopic Severity of Disease

Risk Factors for Colectomy

Induction Therapy for Outpatient at High Risk for Colectomy

Patient Refuses Biologic, Corticosteroid, and Immunomodulator Therapy

Two Sigmoidoscopic Scenarios

Revisit Pathway Options With Patient

Safety Matters

Loss of Response to Anti-TNF Therapy

Case: Anti-TNF Therapy Fails to Induce Remission

Benefits of Mucosal Healing After Corticosteroids in UC

What is Remission?

Adjusting Biologic Therapy, and Thiopurine Withdrawal

Summary

Abbreviations